Recent Posts
- Nature: Protein degraders push into novel target space
- SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
- SEED Therapeutics Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
- SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
- SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
Recent Comments